Chairman: Narayan K Seshadri

Founded: 1979

Headquarters: Bengaluru, Karnataka

Parent organization: Astra Pharmaceuticals AB

Employees: 1325

Profile

AstraZeneca Pharma India Limited is a global biopharmaceutical company. 

The Company is engaged in the discovery, development, and commercialization of medicines for healthcare, including cardiovascular/metabolic disease, cancer, and respiratory, inflammatory, and autoimmune disease. 

The Company operates through two segments: 

a. Healthcare.

b. Clinical Trial. 

The Healthcare segment engages in the manufacture and sale of pharmaceutical products. 

The Clinical Trial segment renders clinical trial services on pharmaceutical products to its group companies. 

 

 

Awards and Achievements

1. It was promoter jointly by Astra Pharmaceuticals AB Sweden (Astra), and IDL Chemicals Ltd Hyderabad.
2. 1980: The Company entered into a technical collaboration with Astra
3. The Company supply for information and know-how and all manufacturing process and technical data for the manufacture of basic drugs, formulations, fine chemicals, and industrial chemicals.
4. The Company undertook to set up a project at Yelahanka Bangalore for the manufacture of basic drugs, formulations, fine including industrial chemicals. 
5. 1982: The pharmaceuticals and chemicals plant was commissioned in February
6. 1982-2,000: shares issued to promoters etc. 24,98,000 shares issued at par 6,43,235 shares each allotted to Astra Pharmaceuticals AB Sweden and IDL Chemicals Ltd 3,78,830 shares allotted to Indian directors, shareholders, and employees, shareholders, and employees, etc. of the company and 8,32,700 shares offered for public subscription.
7. 1988: The Company launched `SENSORCAINE' a long-acting local anesthetic for use in surgical anesthesia and introduced`THEOBRIC' a combination of Branco dilator for asthma. 
8. The Company launched`RESTOMYCIN' an antibiotic
9. `BROMENYL' cough expectorant and `FEBRAFEN' for pain and fever.
10. The Company launched `PROSTODIN'the first prostaglandin with an important indication for postpartum hemorrhage etc. Several new products were launched during the year, namely, SELOPRES, BETALOC DURULES, TRIPRES, SENSORCAINE SPINAL, and BRICANYL, NEBULISING SOLUTION. 
11. It launched products based on inhalation therapy such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER.
12. 1991: The Company launched a product in the Prostaglandins range`PIMIPROST' for the promotion of safe motherhood.
13. 1992: The Company launched Prostaglandin`Cerviprime Gel' for cervical ripening and `Plendil' a new generation calcium antagonist. 
14. 1994: The Company proposed to launch Ramace, Rhinocort, and Imdur. which strengthens the cardiovascular range of products. 
15. 1995: 25,00,000 bonus shares issued in prop. 1:1.
16. 1996: Two new lines of extension namely Jumbo pack of Pulmicort & Bricanyl Inhalers 400 metered doses were introduced in the respiratory group. 
17. 1997: A range of new products viz Xylocaine Spray in the pain control segment, Stop-it in the Anti-infective segment.
18. A joint venture between the US $ 7-billion Swedish pharmaceutical major Astra AB and IDL Industries of the Hindujas.
19. 1998: Wipro, Honda Siel Power Products, and Astra-IDL have been conferred the Analyst Awards by The Institute of Chartered Financial Analysts of India (ICFAI).
20. 1999: Even as the Hindujas continue to seek new alignments to replace multinational AstraZeneca in their joint venture Astra IDL Ltd.
21. 2000: UB's 100 percent subsidiary, UB Bioteck has tied